Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2010

View Archived Issues

In vivo data support clinical development of VX15/2503 for MS

OBA-19 offers neuroprotection in model of ischemic stroke

Firategrast suppresses onset of new lesions in relapsing-remitting MS

Telatinib shows promise in patients with cancer of the stomach or gastroesophageal junction

Phase II/III data support teriflunomide monotherapy for relapsing MS

New antagonists of transient receptor potential TRPA1 channel claimed

Theravance announces results from phase I/II TD-1211 studies

Quark Pharma begins phase I QPI-1007 trial for ocular neuroprotection

Risk of abnormal heart rhythm added to Invirase label

Depomed delivers prototype formulation of fixed-dose metformin/canagliflozin

Phase III trial of clofarabine/cytarabine combination in leukemia meets secondary endpoints

Biogen Idec and Genentech amend collaboration agreement on CD20-targeting antibodies

Trastuzumab approved by FDA for HER2-positive metastatic stomach cancer

BioMarin claims new benzoxazole derivatives for dystrophy and cachexia

Phase IIb trial of inhaled liposomal ciprofloxacin meets primary endpoint

Merck & Co. claims new P2X3 receptor antagonists

Enrollment suspended in ACT 5 trial of vernakalant hydrochloride

ACADIA claims new serotonin 5-HT2A receptor modulators

Phase III data presented on oral calcitonin in osteoarthritis

CHMP issues positive opinion on ranibizumab for DME-related vision impairment

PolyMedix plans phase II studies of PMX-60056

Flamel Technologies achieves milestone for extended release interferon beta-1a

Advaxis advances phase II ADXS11-001 trial in cervical dysplasia

FDA requests additional information in complete response letter on lorcaserin NDA

Phase II study of Intercell's IC-43 meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...